These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 16531813

  • 1. Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies.
    Barbin K, Stieglmaier J, Saul D, Stieglmaier K, Stockmeyer B, Pfeiffer M, Lang P, Fey GH.
    J Immunother; 2006; 29(2):122-33. PubMed ID: 16531813
    [Abstract] [Full Text] [Related]

  • 2. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
    Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P.
    Biotechnol Bioeng; 2006 Apr 05; 93(5):851-61. PubMed ID: 16435400
    [Abstract] [Full Text] [Related]

  • 3. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M.
    Biotechnol Bioeng; 2001 Aug 20; 74(4):288-94. PubMed ID: 11410853
    [Abstract] [Full Text] [Related]

  • 4. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.
    Schuster M, Umana P, Ferrara C, Brünker P, Gerdes C, Waxenecker G, Wiederkum S, Schwager C, Loibner H, Himmler G, Mudde GC.
    Cancer Res; 2005 Sep 01; 65(17):7934-41. PubMed ID: 16140965
    [Abstract] [Full Text] [Related]

  • 5. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.
    Glycobiology; 2007 Jan 01; 17(1):104-18. PubMed ID: 17012310
    [Abstract] [Full Text] [Related]

  • 6. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W, Nishioka Y, Ozaki S, Jalili A, Verma VK, Hanibuchi M, Abe S, Minakuchi K, Matsumoto T, Sone S.
    Lung Cancer; 2009 Jan 01; 63(1):23-31. PubMed ID: 18524412
    [Abstract] [Full Text] [Related]

  • 7. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M.
    Biotechnol Bioeng; 2004 Sep 05; 87(5):614-22. PubMed ID: 15352059
    [Abstract] [Full Text] [Related]

  • 8. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.
    Nechansky A, Schuster M, Jost W, Siegl P, Wiederkum S, Gorr G, Kircheis R.
    Mol Immunol; 2007 Mar 05; 44(7):1815-7. PubMed ID: 17011625
    [Abstract] [Full Text] [Related]

  • 9. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH.
    Br J Haematol; 2005 Jul 05; 130(2):218-28. PubMed ID: 16029450
    [Abstract] [Full Text] [Related]

  • 10. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.
    Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE.
    Nat Biotechnol; 1999 Feb 05; 17(2):176-80. PubMed ID: 10052355
    [Abstract] [Full Text] [Related]

  • 11. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells.
    Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, Barbin K, Stein C, Peipp M, Stockmeyer B, Fey GH.
    Cancer Lett; 2011 Apr 28; 303(2):128-39. PubMed ID: 21339041
    [Abstract] [Full Text] [Related]

  • 12. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):151-60. PubMed ID: 16219319
    [Abstract] [Full Text] [Related]

  • 13. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):93-103. PubMed ID: 16236307
    [Abstract] [Full Text] [Related]

  • 14. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.
    Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, Inagaki H, Okada N, Fujita T, Shitara K, Akinaga S, Takahashi T, Utsunomiya A, Ueda R.
    Clin Cancer Res; 2004 Nov 15; 10(22):7529-39. PubMed ID: 15569983
    [Abstract] [Full Text] [Related]

  • 15. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.
    Cancer Res; 2008 Oct 01; 68(19):8049-57. PubMed ID: 18829563
    [Abstract] [Full Text] [Related]

  • 16. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.
    J Immunol; 2009 Oct 01; 183(7):4782-91. PubMed ID: 19748990
    [Abstract] [Full Text] [Related]

  • 17. Reduction of N-linked xylose and fucose by expression of rat beta1,4-N-acetylglucosaminyltransferase III in tobacco BY-2 cells depends on Golgi enzyme localization domain and genetic elements used for expression.
    Karg SR, Frey AD, Kallio PT.
    J Biotechnol; 2010 Mar 01; 146(1-2):54-65. PubMed ID: 20083147
    [Abstract] [Full Text] [Related]

  • 18. Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
    Nishimura Y, Yokoyama M, Araki K, Ueda R, Kudo A, Watanabe T.
    Cancer Res; 1987 Feb 15; 47(4):999-1005. PubMed ID: 2948638
    [Abstract] [Full Text] [Related]

  • 19. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH.
    J Immunother; 2008 Feb 15; 31(9):871-84. PubMed ID: 18833000
    [Abstract] [Full Text] [Related]

  • 20. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ, Ausubel L, Gutierrez M, Stephan S, Shakeley R, Olivares S, Serrano LM, Burton L, Jensen MC, Forman SJ, DiGiusto DL.
    Cytotherapy; 2006 Feb 15; 8(2):105-17. PubMed ID: 16698684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.